Scarica l'app Stockscreener
0.8199
3.26%
0.0259
Dopo l'orario di chiusura:
.78
-0.0399
-4.87%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.794
Aprire:
$0.7936
Volume 24 ore:
89,844
Relative Volume:
0.24
Capitalizzazione di mercato:
$15.15M
Reddito:
-
Utile/perdita netta:
$-25.56M
Rapporto P/E:
-0.1577
EPS:
-5.2
Flusso di cassa netto:
$-19.35M
1 W Prestazione:
-0.15%
1M Prestazione:
-26.80%
6M Prestazione:
-75.60%
1 anno Prestazione:
-83.03%
Intervallo 1D:
$0.771
$0.8383
Intervallo di 1 settimana:
$0.75
$0.855
Portata 52W:
$0.62
$7.50
Biovie Inc Stock (BIVI) Company Profile
Nome
Biovie Inc
Settore
Industria
Telefono
775-888-3162
Indirizzo
680 W NYE LANE, CARSON CITY
Confronta BIVI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
0.8199 | 15.15M | 0 | -25.56M | -19.35M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-15 | Iniziato | B. Riley Securities | Buy |
Biovie Inc Borsa (BIVI) Ultime notizie
BioVie (NASDAQ:BIVI) Trading Down 5.6% – Should You Sell? - Defense World
Financial Contrast: BioVie (NASDAQ:BIVI) vs. DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim In Early Parkinson's Disease - Nasdaq
BioVie (BIVI) Launches Phase 2 SUNRISE-PD Trial for Parkinson's Treatment | BIVI Stock News - GuruFocus
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled - GlobeNewswire
Breakthrough Parkinson's Drug Enters Critical Phase 2 Trial: First Patient Dosed - Stock Titan
New to The Street's FOX Business "Late Night T.V." Special Airs Tonight – Show #650 – Featuring Health In Tech CEO Julia Qian (NASDAQ:HIT), BioVie's Dr. Joseph Palumbo (NASDAQ:BIVI), eXoZymes Co-Founder & VP of Research Tyler Korman (EXOZ), a - voiceofalexandria.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of BioVie Inc.(BIVI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice - Hastings Tribune
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vic - voiceofalexandria.com
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vi - Newswire.com
Constellation Brands Q4 2025 Earnings Call Transcript - MarketBeat
ALERT: Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class - TradingView
UPCOMING BIVI DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds BioVie Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024BIVI - ACCESS Newswire
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: - GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); a - Morningstar
BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman - ACCESS Newswire
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events - ACCESS Newswire
Biovie stock hits 52-week low at $0.98 amid sharp annual decline - Investing.com Canada
Biovie stock hits 52-week low at $0.98 amid sharp annual decline By Investing.com - Investing.com South Africa
BioVie Investors Advance Lawsuit Over Alzheimer's Drug Trial - Bloomberg Law News
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - ACCESS Newswire
BioVie announces board member resignation By Investing.com - Investing.com South Africa
BioVie announces board member resignation - Investing.com India
BioVie to Host KOL Investor Webcast to Discuss the Long - GlobeNewswire
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025 - The Manila Times
Yale KOL Reveals Latest Long COVID Breakthrough: BioVie's Novel Treatment Shows Promise - Stock Titan
New to The Street’s FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese’s The Big Skinny on eXoZymes, and B - Hilton Head Island Packet
New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and B - ACCESS Newswire
Brokers Set Expectations for BioVie Q3 Earnings - Defense World
BioVie (NASDAQ:BIVI) Upgraded at Brookline Capital Management - Defense World
Brookline Capital sets $6 target on BioVie stock with Buy rating - Investing.com
Biovie stock plunges to 52-week low, touches $1.04 By Investing.com - Investing.com India
Biovie stock plunges to 52-week low, touches $1.04 - Investing.com
Biovie Inc Azioni (BIVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):